Neurogene Inc. (NGNE)
NASDAQ: NGNE
· Real-Time Price · USD
18.95
-0.02 (-0.11%)
At close: Jun 17, 2025, 10:46 AM
-0.11% (1D)
| Bid | 18.64 |
| Market Cap | 270.34M |
| Revenue (ttm) | 925K |
| Net Income (ttm) | -80.87M |
| EPS (ttm) | -4.36 |
| PE Ratio (ttm) | -4.35 |
| Forward PE | -3.91 |
| Analyst | Buy |
| Ask | 19.52 |
| Volume | 46,095 |
| Avg. Volume (20D) | 274,865 |
| Open | 21.43 |
| Previous Close | 18.97 |
| Day's Range | 18.91 - 19.90 |
| 52-Week Range | 6.88 - 74.49 |
| Beta | 1.58 |
About NGNE
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol NGNE
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for NGNE stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts1 month ago
-7.12%
Neurogene shares are trading lower after Baird dow...
Unlock content with
Pro Subscription
7 months ago
-42.58%
Neurgogene shares are trading lower after the company announced it brought its high-dose gene therapy trial to a halt after a serious adverse event in a Rett syndrome patient.
